Pfizer offers Pfizer Oncology Together, a patient support program to help patients access their prescribed Pfizer Oncology medications, identify financial assistance options, and connect patients to a dedicated Care Champion. A complete list of Pfizer Oncology medications and their related assistance programs is provided in the Table.
Pfizer Oncology Together
Pfizer Oncology Together offers the Pfizer Oncology Together Co-Pay Savings Program, the Pfizer Patient Assistance Program, and the Care Champion Program.
Pfizer Oncology Together Co-Pay Savings Program
Copay savings are available for eligible, commercially insured patients who are prescribed certain Pfizer Oncology oral or injectable medications. Limits, terms, and conditions apply depending on the medication prescribed. Click here to learn more or to enroll your patient in the Pfizer Oncology Together Co-Pay Savings Program.
Pfizer Patient Assistance Program
Through the Pfizer Patient Assistance Program, uninsured patients may receive free medication for up to 1 calendar year, while underinsured patients are enrolled through the end of the calendar year. To be evaluated for assistance through this program, you and your patient must each submit a completed enrollment form. Patients must also provide proof of income, such as the prior year’s tax return, a W-2 form, or paycheck stub. Patients must also:
Have a valid prescription from a healthcare provider licensed in the United States or a US territory for a Pfizer medication
Have no prescription coverage, or not enough coverage, to pay for their Pfizer medication
Meet certain income limits, which are subject to change on an annual basis and will vary depending on household size
Reside in the United States or a US territory
Not be treated in an inpatient setting of care, such as a hospital or nursing home.
Click here to learn more or to enroll your patient in the Pfizer Patient Assistance Program.
Care Champion Program
The Care Champion Program is a free patient support program for patients prescribed a Pfizer Oncology medication. Patients are partnered with a dedicated Care Champion who has social work experience and can provide resources that may help with some of their daily challenges, no matter where they are in the treatment journey. Click here to learn more or to enroll your patient in the Care Champion Program.
Free Trial Vouchers
Patients who have been newly prescribed certain Pfizer Oncology medications may be able to start therapy with a free trial voucher. Click here to learn more or to find out which medications offer trial vouchers, or see Table.
Treatment of non-Hodgkin lymphoma: alone or with other chemotherapy medicines; chronic lymphocytic leukemia with the chemotherapy medicines fludarabine and cyclophosphamide; granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis with glucocorticoids
To decrease infection (ie, febrile neutropenia) in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs; reduce time to neutrophil recovery and fever, after chemotherapy in patients with acute myeloid leukemia; reduce duration of neutropenia and neutropenia-related sequelae in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by transplant; for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis; to reduce incidence/duration of neutropenia sequelae in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
Zirabev (bevacizumab-bvzr) Indications
First-line treatment of unresectable, locally advanced, recurrent or metastatic NSCLC, in combination with carboplatin and paclitaxel; treatment of adults with recurrent glioblastoma; treatment of metastatic RCC, in combination with interferon alfa; treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan; epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by Zirabev as a single agent, for stage III or IV disease following initial surgical resection or in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens or in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Zirabev as a single agent, for platinum-sensitive recurrent disease; metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment; metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan– or fluoropyrimidine-oxaliplatin–based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product–containing regimen
